<DOC>
	<DOCNO>NCT02967276</DOCNO>
	<brief_summary>This phase II trial study assess activity metformin give together high dose dexamethasone treat patient multiple myeloma ( MM ) relapse refractory previous treatment . High dose dexamethasone ( HDdexa ) use treat relapse/refractary patient myeloma metformin also demonstrate synergistic activity dexamethasone eradicate MM cell vitro vivo . Metformin hydrochloride , use diabetes , may also help kill tumor cell . Giving dexamethasone metformin may kill MM cell increase response rate HDdexa .</brief_summary>
	<brief_title>Clinical Activity Metformin With High-dose Dexamethasone Relapse Multiple Myeloma</brief_title>
	<detailed_description>Phase II trial , open label , clinical activity metformin combination high-dose dexamethasone ( HDdexa ) patient multiple myeloma relapsed-refractory . If find eligible take part study , metformin give continuously completion treatment , disease progression , severe toxicity intolerance . The duration treatment apply dexamethasone . The treatment initiate dexamethasone ( 40 mg daily 4 day D1-D4 , D9-D12 D17-D20 ) Before start HDDexa investigator obtain blood bone marrow sample evaluation response disease use biomarkers multiple myeloma . On day 1 , patient begin metformin XR ( 500mg daily even meal ) gradual increase dose - 500 mg per week maximum 2.5 g / day toxicity grade ≥ 2 . Each cycle reset every 35 day 1st 2nd cycle every 28 day 3rd 6th cycle . Patients maintain clinical response treatment first cycle use drug 6 cycle , progression unacceptable toxicity . Oral dexamethasone ( 40 mg ) administer day 1 4 , 9 12 17 20 first second ( cycle 35 day ) day 1 , 8 , 15 22 third sixth ( cycle 28d ) , period 190 day treatment . Patients 75 year use 20 mg / day instead 40 mg / day . Patients submit collection tissue : blood bone marrow evaluate response disease multiple myeloma biomarkers first cycle , 4th 5th cycle treatment ass response accord IMWG criterion : blood count , creatinine , calcium , lactate dehydrogenase ( LDH ) ; Beta2 microglobulin ; C-reactive protein ( CRP ) erythrocyte sedimentation rate ( ESR ) ; Immunoelectrophoresis immunofixation proteins serum urine 24 hour ; 24h proteinuria ; Myelogram bone marrow biopsy ( BMO ) Immunophenotyping . Clinical laboratory exam conduct begin every 35 day first 2 cycle every 28 day 6th cycle . Safety assessment include history physical examination , electrocardiography , blood count , biochemical test ( include glucose glycated Hb ) pulse oximetry . Toxic effect analyze accord National Cancer Institute Common Toxicity Criteria Adverse Events , version 4 ( NCI CTCAE v4 ) . This investigational study . Dexamethasone FDA approve commercially available treatment many inflammatory disease . Metformin FDA approve commercially available treatment diabetes mellitus . The combination drug treat multiple myeloma investigational . Up 28 patient take part study . This multicenter study , take place clinical research center Clinical Hematology Clinical Hospital , University Campinas-UNICAMP Cascavel Cancer Hospital - UOPECCAN . This study coordinate Hemocentro-UNICAMP</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients 18 year ; Multiple myeloma patient relapse refractory two line prior treatment [ least one line use bortezomib prior treatment suitable alkylating agent ( least six cycle treatment alkylating progressive disease least two cycle treatment alkylating treatment alkylating receive part stem cell transplant ) ] ; Patients fail ( progressive disease 60 day treatment , disease progression ≤6 month achieve partial response intolerance bortezomib ) treatment bortezomib ; Patients oral access medicine ; ECOG ≤ 2 ; Blood count : hemoglobin ≥8 g / dL ; absolute neutrophil count ≥500 / mm3 platelet count ≥30.000 / mm3 , glomerular filtration rate ( GFR ) ≥60ml / min adequate liver function ( AST ALT level 3x upper limit normal , bilirubin level great 2x upper limit normal , negative pregnancy test study initiation accept contraceptive use . Patients know hypersensitivity / prior therapy metformin excipients ; Diabetes mellitus require insulin use oral hypoglycemic agent ; patient history hyperglycemia induce steroid enter since HbA1C screen visit &lt; 8 % ; leptomeningeal brain metastasis symptomatic untreated , spinal cord compression ; Known human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) ( exception treat cure chronic HBV HCV infection , allow ) ; Patients use another study medication receive drug study le 4 week ; It allow concomitant treatment bisphosphonates ; however , treatment start first dose study therapy ; allow use herbal supplement study ( include , limited , St. John 's wort , kava , None , gingko biloba , dehydroepiandrosterone [ DHEA ] , ginseng ) . megestrol acetate ( Megace ) medroxyprogesterone use appetite stimulant permit ; Uncontrolled situation intercurrent disease , include , limited , infection ongoing active , refractory systemic hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric / social disease would limit compliance requirement study ; Previous Neoplasms , except skin cancer two year ; Patients pregnant breastfeeding . Any major surgery , extensive radiation therapy , chemotherapy delay toxicity , biological therapy , chemotherapy immunotherapy within 28 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>